Innovating Works

DERMAREP

Financiado
Clinical validation and production upscaling of a novel product for healing of P...
Clinical validation and production upscaling of a novel product for healing of Pressure Ulcers Leg Ulcers and Diabetic Foot Ulcers. A chronic wound (such as Leg Ulcer (LU), Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) can be defined as one that has failed to proceed through an orderly and timely reparative process to produce anatomic and functional integr... A chronic wound (such as Leg Ulcer (LU), Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) can be defined as one that has failed to proceed through an orderly and timely reparative process to produce anatomic and functional integrity within a period of 3 months or that has proceeded through the repair process without establishing a sustained and anatomic and functional result. Chronic wounds may require several years to heal, and some remain unhealed for decades. During this time, patients can experience severe pain, significant emotional and physical distress, reduced mobility and social isolation. LU, PU and DFU are a major healthcare cost for all developed countries. The main driver for growth in cost is the treatment of chronic and complex wounds in the aging population, complicated by the increase in diabetes and other metabolic disorders. LUs account for $50Bn of global wound care burden in 2015 and are to reach $53Bn in 2020. DFUs account for $52Bn – and are to reach $56Bn by 2020. Further, PUs account for $41Bn of global wound care burden in 2015 – and are to reach $47Bn by 2020. We have developed an innovative wound dressing, DermaRep™, that is based on biomaterial derived from Eggshell Membrane (ESM) – a by-product readily available in the egg industry. The purified form of ESM is called Purified Eggshell Membrane Protein (PEP). DermaRep™ is disruptive and will become the benchmark in the wound healing market as it directly addresses the healthcare needs by providing a novel wound care product that is significantly more effective than current Standard of Care (SoC, relatively non-expensive silicon, foam and hydrocolloid dressings) and at least as effective as existing State of the Art (SoA) collagen-based dressings. ver más
31/03/2023
Innovasjon Norge
4M€
Duración del proyecto: 42 meses Fecha Inicio: 2019-09-30
Fecha Fin: 2023-03-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-03-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-FTI-2018-2020: Fast Track to Innovation (FTI)
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.